Selection of the mobilization regimen in lymphoma patients: A retrospective cohort study

Sarıcı, Ahmet; Erkurt, Mehmet Ali; Kuku, İrfan; Gök, Selim; Bahçecíoğlu, Ömer Faruk; Biçim, Soykan; Berber, İlhami; Kaya, Emin; Özgül, Mustafa

doi:10.1016/j.transci.2021.103251

Cited by 3 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who were administered DHAP in addition to G-CSF exhibited a greater CD34 + count, and their neutrophil engraftment time was shorter than those who received ESHAP along with G-CSF (P < 0.05) [40]. Many studies have also con rmed that DHAP scheme is an effective mobilization scheme for NHL [40,41]. For mantle cell lymphoma, use of R-hyper CVAD chemotherapy was associated with signi cantly higher rates of hematopoietic progenitor cell collection failures (17%) [42].…”

Section: Discussionmentioning

confidence: 96%

“…Besides, the number of CD34 cells collected was higher with the DHAP (dexamethasone, cytarabine, and cisplatin) + CSF chemotherapy mobilization regimen compared to the ESHAP (etoposide, methylprednisolone, etoposide, and methylprednisolone [ESHAP]) regimen. Patients who were administered DHAP in addition to G-CSF exhibited a greater CD34 + count, and their neutrophil engraftment time was shorter than those who received ESHAP along with G-CSF (P < 0.05) [40]. Many studies have also con rmed that DHAP scheme is an effective mobilization scheme for NHL [40,41].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chinese experience in hematopoietic stem cell mobilization and collection in lymphoma patients: a retrospective cohort study

Lv,

Mi,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Lymphoma can be treated with autologous hematopoietic stem cell transplantation. The mobilization and collection of hematopoietic stem cells is essential for the success of stem cell transplantation. From January 2017 to December 2022, 561 patients who had undergone autologous hematopoietic stem cell mobilization and collection at Peking University Cancer Hospital were analyzed retrospectively. In the post-plerixafor era, the parameters of the mobilization and collection of stem cells have changed. Some factors still influence the number of stem cells collected, such as age, pre-apheresis blood platelet counts, peripheral blood CD34 + cells; However, the pathological type of patients, bone marrow infiltration, number of treatment lines, and whether small molecule drugs such as lenalidomide were used had no significant effect on the number of CD34 + cells collected. Although the number of CD34 + cell yields in chemo-mobilization is indeed higher than that in steady-state mobilization, clinicians also need balance benefits versus risks to select appropriate mobilization regimens. Plerixafor as a new mobilizer can improve the results of CD34 + cell yields, with cost-effectiveness being taken into account.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Chinese experience in hematopoietic stem cell mobilization and collection in lymphoma patients: a retrospective cohort study

Lv,

Mi,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…As for patients with NHL, benefits of CY in HSCs mobilization are uncertain, the two RCTs enrolling participants before the year of 2000 to compare the efficacy of CY plus G-CSF versus G-CSF alone did not reach consistent conclusions [ 49 , 51 ]. Nowadays, salvage therapy regimens such as DHAP, ESHAP, ICE and IEV (ifosphamide, epirubicin and etoposide) follow by G-CSF is a commonly used HSCs mobilization approach for patients with relapsed or refractory NHL, it eliminates the requirement of additional chemotherapy [ 74 , 75 ]. A RCT comparing DHAP versus CY did not report significant difference in mean number of CD34 + cells collected [ 54 ].…”

Section: Discussionmentioning

confidence: 99%

“…RCTs comparing other salvage therapy regimens are not available. Retrospective studies comparing the mobilization efficacy of different chemotherapy regimens in NHL patients reported inconsistent results in different study design [ 75 – 77 ].Other mobilizing chemotherapy regimens including etoposide alone, ifosphamide alone, CE (cyclophosphamide, etoposide), CEP (cyclophosphamide, etoposide, and cisplatin), MEOD with or without MTX are also investigated, but the related trials failed to be integrated in our network meta-analysis due to the heterogeneity in study design and the lack of connection to the main network [ 29 , 53 , 62 – 64 , 67 ]. In addition, mobilizing chemotherapy regimens varies across different disease subgroups and study centers.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials

Luo

Huang

et al. 2022

Stem Cell Res Ther

View full text Add to dashboard Cite

Background Efficient mobilization of hematopoietic stem cells (HSCs) from bone marrow niche into circulation is the key to successful collection and transplantation in patients with hematological malignancies. The efficacy of various HSCs mobilization regimens has been widely investigated, but the results are inconsistent. Methods We performed comprehensive databases searching for eligible randomized controlled trials (RCTs) that comparing the efficacy of HSCs mobilization regimens in patients with hematological malignancies. Bayesian network meta-analyses were performed with WinBUGS. Standard dose of granulocyte colony-stimulating factor (G-CSF SD) was chosen as the common comparator. Estimates of relative treatment effects for other regimens were reported as mean differences (MD) or odds ratio (OR) with associated 95% credibility interval (95% CrI). The surface under the cumulative ranking curve (SUCRA) were obtained to present rank probabilities of all included regimens. Results Databases searching and study selection identified 44 eligible RCTs, of which the mobilization results are summarized. Then we compared the efficacy of mobilization regimens separately for patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) by including 13 eligible trials for network meta-analysis, involving 638 patients with MM and 592 patients with NHL. For patients with MM, data are pooled from 8 trials for 6 regimens, including G-CSF in standard dose (SD) or reduced dose (RD) combined with cyclophosphamide (CY), intermediate-dose cytarabine (ID-AraC) or plerixafor. The results show that compared with G-CSF SD alone, 3 regimens including ID-AraC + G-CSF SD (MD 14.29, 95% CrI 9.99–18.53; SUCRA 1.00), G-CSF SD + Plerixafor SD (MD 4.15, 95% CrI 2.92–5.39; SUCRA 0.80), and CY + G-CSF RD (MD 1.18, 95% CrI 0.29–2.07; SUCRA 0.60) are associated with significantly increased total number of collected CD34+ cells (× 106/kg), among which ID-AraC + G-CSF SD ranked first with a probability of being best regimen of 100%. Moreover, ID-AraC + G-CSF SD and G-CSF SD + Plerixafor SD are associated with significantly higher successful rate of achieving optimal target (collecting ≥ 4–6 × 106 CD34+ cells/kg). For patients with NHL, data are pooled from 5 trials for 4 regimens, the results show that compared with G-CSF SD alone, G-CSF SD + Plerixafor SD (MD 3.62, 95% CrI 2.86–4.38; SUCRA 0.81) and G-CSF SD plus the new CXC chemokine receptor-4 (CXCR-4) antagonist YF-H-2015005 (MD 3.43, 95% CrI 2.51–4.35; SUCRA 0.69) are associated with significantly higher number of total CD34+ cells collected. These 2 regimens are also associated with significantly higher successful rate of achieving optimal target. There are no significant differences in rate of achieving optimal target between G-CSF SD + Plerixafor SD and G-CSF + YF-H-2015005. Conclusions In conclusion, ID-AraC plus G-CSF is associated with the highest probability of being best mobilization regimen in patients with MM. For patients with NHL, G-CSF in combination with plerixafor or YF-H-2015005 showed similar improvements in HSCs mobilization efficacy. The relative effects of other chemotherapy-based mobilization regimens still require to be determined with further investigations.

show abstract

“…Cyclophosphamide (CYP) is one of the most successful chemotherapeutic agents available and is still extensively used in a wide range of diseases, alone and in combination with other therapies. These conditions include lupus, rheumatoid arthritis, neoplasms, nephrotic syndrome and conditioning of regimens for blood and marrow transplantation (Emadi et al, 2009; Sarici et al, 2021). The early clinical trials of cyclophosphamide for the treatment of neoplasms were carried out in 1958, and in 1959 (Brock & Wilmanns, 1958), and subsequently became one of the first sets of cancer chemotherapeutic agents approved by the food and drug authority (Muggia et al, 1980).…”

Section: Introductionmentioning

confidence: 99%

Oral thymoquinone modulates cyclophosphamide‐induced testicular toxicity in adolescent Wistar rats

et al. 2022

View full text Add to dashboard Cite

Cyclophosphamide (CYP) is an effective anti‐cancer drug that is widely accepted, but it is not devoid of unintended toxic effects. Gonadal toxicity is reported as one of the side effects of its long‐time use. This study examined the effects of thymoquinone (TQ) on the biological integrities of the testes after cyclophosphamide exposure. Thirty adolescent male Wistar rats (100–110 g) were divided into six groups (n = 5), receiving normal saline (NS), 20 mg/kg of CYP (CYP), 5 mg/kg of TQ (TQ5), 10 mg/kg of TQ (TQ10), 20 mg/kg of CYP and 5 mg/kg of TQ (CTQ5), and 20 mg/kg of CYP and 10 mg/kg of TQ (CTQ10) respectively. On the 22nd day, blood, semen and testicular samples were collected for the assay of serum reproductive hormones (follicle‐stimulating (FSH) and luteinizing (LH) hormones), semen analysis and testicular histology and proliferating cell nuclear antigen (PCNA) expression. The results revealed that CYP exposure affected functional and structural integrities of the testes, by depleting sperm count and motility, testosterone, LH, spermatogenic and mature sperm cell population, Leydig cells and PCNA immunoreactive proliferating cells. TQ interventions were able to reverse all cytotoxic CYP impacts, but with differential activities on the hormonal concentrations, specifically LH and FSH. Cumulatively, thymoquinone may be a potent agent against cyclophosphamide effects on the physiological, regeneration and histological integrities of the testes, as observed in this study.

show abstract

Selection of the mobilization regimen in lymphoma patients: A retrospective cohort study

Cited by 3 publications

References 21 publications

Chinese experience in hematopoietic stem cell mobilization and collection in lymphoma patients: a retrospective cohort study

Chinese experience in hematopoietic stem cell mobilization and collection in lymphoma patients: a retrospective cohort study

Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials

Oral thymoquinone modulates cyclophosphamide‐induced testicular toxicity in adolescent Wistar rats

Contact Info

Product

Resources

About